A responsible read on this comparison starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.
Last November, a patient I’ll call Dana sat across from me on a telehealth screen holding a printed-out Reddit thread in one hand and a pharmacy invoice in the other. The invoice was from her local Walgreens: $1,287 cash for a one-month supply of Wegovy. The Reddit thread was a sprawling, partly accurate guide to compounded semaglutide. She wanted to know what was real and what was noise. It’s a version of a conversation I’ve had dozens of times now, and it always starts in the same place: confusion about what compounded semaglutide actually is, whether it works, and who should be cautious.
This is my attempt at the reference I wish I could hand people before that conversation.
The Basics, Without the Marketing Gloss
Semaglutide is a GLP-1 receptor agonist. Novo Nordisk developed it, brought it to market as Ozempic in 2017 for type 2 diabetes, then as Wegovy in 2021 for chronic weight management. Both are FDA-approved finished products.
Compounded semaglutide uses the same active pharmaceutical ingredient. The difference is the supply pathway: a state-licensed or 503A compounding pharmacy prepares it for an individual patient under a clinician’s prescription. It is governed under section 503A of the Federal Food, Drug, and Cosmetic Act and parallel state pharmacy regulations. It is not FDA-approved as a finished product.
That’s a meaningful distinction, but it doesn’t mean what a lot of people assume it means. Compounding pharmacies have prepared medications across dozens of drug classes for years. This pathway isn’t new, and it isn’t unique to GLP-1 therapy. What’s new is the volume of demand, which has pulled the practice into consumer-facing visibility in a way compounding hasn’t experienced before.
How the Drug Works (and What the Trials Actually Show)
GLP-1 is an incretin hormone your intestinal L-cells secrete after you eat. Semaglutide mimics that hormone with a long enough half-life to support once-weekly dosing. Its clinically meaningful actions: it stimulates insulin secretion (but only when glucose is elevated, which matters for safety), suppresses glucagon after meals, slows gastric emptying, and reduces appetite through hypothalamic signaling. The appetite piece is the one patients notice first. The gastric emptying piece is why you feel full faster. Together, they produce the weight and metabolic effects the trials documented.
About those trials.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide arm lost approximately 14.9% of body weight from baseline versus 2.4% in the placebo arm (Wilding et al., New England Journal of Medicine, 2021). That’s a large, well-powered trial with a clear result. STEP-3 added intensive behavioral therapy and showed a directionally similar but somewhat larger effect. STEP-5 extended follow-up to 104 weeks and reported sustained weight reduction in the active arm.
On the diabetes side, the SUSTAIN program established glycemic and cardiovascular benefits at lower doses (typically 0.5 mg and 1.0 mg weekly, with 2.0 mg added in SUSTAIN FORTE). SUSTAIN-6, the cardiovascular outcome trial, reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population (Marso SP et al.).
Here’s the important caveat: all of that evidence was generated using the brand-name finished product. The data informs our understanding of compounded semaglutide (same molecule, same mechanism), but compounded preparations have not been studied as finished products in registrational trials. I think it’s reasonable to extrapolate, carefully, but you should know the distinction exists.
Titration, Dosing, and the Stuff That Shapes Your Daily Experience
The standard titration from the STEP trials and the Wegovy label runs five steps over roughly sixteen to seventeen weeks:
- 0.25 mg weekly for four weeks
- 0.5 mg weekly for four weeks
- 1.0 mg weekly for four weeks
- 1.7 mg weekly for four weeks
- 2.4 mg weekly as maintenance
Most compounded programs use identical milligram increments. What varies is the concentration of the preparation and the volume you draw into the syringe. This trips people up constantly. If you’re switching between programs or pharmacies, confirm the milligram dose at each step, not the volume. A 0.5 mL injection from one pharmacy and a 0.25 mL injection from another may deliver the exact same dose.
The schedule is flexible. A patient nauseated at 0.5 mg can stay there for another four weeks before stepping up. A patient doing well clinically at 1.7 mg can elect to stay rather than push to 2.4 mg. This is a clinical decision, not a checkbox. Good programs treat it that way.
Storage: refrigerate at 36 to 46 degrees Fahrenheit. Limited time at room temperature is fine for transport, but don’t leave it on your kitchen counter overnight. Rotate injection sites between abdomen, thigh, and upper arm to reduce local irritation. Pick a consistent day of the week. That’s about it for the operational side.
Side Effects: What’s Common, What’s Rare, What’s Serious
Gastrointestinal symptoms dominate. Nausea, diarrhea, constipation, vomiting, and abdominal discomfort showed up across both the STEP and SUSTAIN programs and show up consistently in real-world cohorts. For most patients, these are mild to moderate, concentrated in the first eight to twelve weeks, and resolve with continued therapy or a temporary dose hold. The boring truth is that careful titration prevents a lot of it.
Less common but clinically important: gallbladder events (especially with rapid weight loss), acute pancreatitis (rare but requiring prompt evaluation), and a theoretical signal for thyroid C-cell tumors based on rodent data that has not been replicated in humans. Both the Wegovy and Ozempic labels carry a boxed warning about the thyroid C-cell finding in rats and a contraindication for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Hypoglycemia on semaglutide alone in non-diabetic patients is uncommon because the insulin stimulation is glucose-dependent. The risk climbs when semaglutide is stacked with insulin or sulfonylureas in the diabetes setting; dose adjustment of those agents is the relevant intervention.
Patients on warfarin or other medications with narrow therapeutic windows should flag the slowed gastric emptying effect, which can alter absorption timing of concurrent medications.
The Cost Reality
Brand-name Wegovy and Ozempic carry a list price above $1,300 per month in the United States. Cash-pay rates at most retail pharmacies land between $1,000 and $1,400. Insurance coverage for weight-management indications remains inconsistent. The diabetes indication has better coverage, but it still varies meaningfully by plan.
Compounded semaglutide programs in compliant telehealth structures price substantially below that. HealthRX, for example, runs $179.99 to $279.99 per month depending on dose, is available in 44 US states, and operates under LegitScript certification.
The pricing gap isn’t a mystery or a red flag. Brand-name finished products carry the full cost of manufacturing scale-up, regulatory submissions, post-marketing surveillance, and the commercial margin that funds the next generation of research. Compounded preparations are produced at a different scale through a different regulatory pathway with a different cost structure. It’s a bit like the difference between a mass-produced car and one built to order from the same engine, if the engine were the expensive part.
If you plan to use an HSA or FSA, confirm the program’s invoicing format before enrollment. Reimbursement eligibility depends on your specific plan and the documentation provided.
Compounded vs. Brand-Name: Framing the Comparison Honestly
This comparison is best understood as two supply pathways for the same active ingredient.
Three practical differences matter:
1. Evidence base. The STEP and SUSTAIN clinical evidence was generated on the brand-name finished product. It informs but does not directly validate compounded preparations.
2. Manufacturing oversight. Compounded pharmacies are regulated by state boards of pharmacy (and, for 503B outsourcing facilities, by the FDA under a different framework than finished-product manufacturers). The oversight model is different, not absent.
3. Adverse-event surveillance. The post-marketing reporting infrastructure is less complete for compounded preparations than for brand-name products.
None of this means compounded semaglutide is inferior or unsafe by default. It means the frameworks are different, and a responsible reference should name that difference rather than paper over it. Patients comparing the two pathways benefit from a conversation with a clinician who has no financial incentive to push them toward either option. What matters is clinical fit, insurance reality, and the patient’s preferred care model.
For readers who want a fuller picture of how these pathways compare, this comparison walks through the questions that typically come up in a real intake and can make that clinical conversation more productive.
When to Call Your Clinician (Not Google)
A handful of scenarios warrant a direct conversation rather than self-management:
- Persistent severe abdominal pain, especially radiating to the back or with fever (pancreatitis red flag)
- Inability to keep down fluids for more than 24 hours, persistent vomiting, or signs of dehydration
- New gallbladder symptoms: right upper quadrant pain after meals, jaundice
- New or worsening reflux that doesn’t respond to meal-timing adjustments
- Mood changes, including new or worsening depressive symptoms
- Pregnancy, planned pregnancy, or breastfeeding (have this conversation before the next dose)
- Hypoglycemic episodes if you’re on concurrent insulin or sulfonylureas
If a personal or family history of medullary thyroid carcinoma or MEN2 wasn’t surfaced at intake, that’s a conversation to have immediately. It’s a contraindication to therapy.
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy? The active ingredient, semaglutide, is the same. The finished product, regulatory category, and manufacturing pathway are different. Brand-name Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.
How long does treatment typically last? STEP-1 captures 68 weeks; STEP-5 extends to 104 weeks; clinical experience now goes beyond two years. Duration is individualized based on the patient’s goals, response, and tolerability.
Is the weight reduction sustained after stopping? STEP-4 showed significant regain in the arm switched to placebo after a lead-in period, suggesting the metabolic effect depends on continued therapy for many patients. Long-term outcomes after discontinuation hinge on the lifestyle changes consolidated during treatment.
Do I need labs to start? A careful program will document baseline labs, which may include a metabolic panel, lipid panel, A1c, and in some patients a thyroid panel. The specific set depends on your clinical picture.
Is semaglutide right for everyone? No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A real intake conversation surfaces these before therapy begins.
What if I can’t tolerate the nausea? Your clinician can hold your current dose for an additional four weeks, reduce the dose temporarily, or adjust meal timing. Most nausea resolves within the first two to three months. If it doesn’t, that’s worth a serious conversation about whether the benefit-risk balance still makes sense for you.
Can I switch between compounded and brand-name semaglutide? Yes, though you should confirm the milligram dose aligns across preparations. The molecule is the same; the transition is about matching the dose, not restarting from scratch.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
